Dr Anthony Cardin
Clinical (Lecturer)
The Sir Peter MacCallum Department of Oncology
24 Scholarly works
0 Projects
HIGHLIGHTS
2025
Journal article
Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis
DOI: 10.2967/jnumed.125.2708042025
Journal article
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
DOI: 10.1016/S1470-2045(25)00559-52025
Journal article
Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours – a single centre experience
DOI: 10.1007/s00259-025-07235-w2025
Journal article
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
DOI: 10.1016/S1470-2045(25)00332-82025
Journal article
Radiological, Pathological, and Surgical Outcomes with Neoadjuvant Cemiplimab for Stage II–IV Cutaneous Squamous Cell Carcinoma in the Deep Sequencing in Cutaneous Squamous Cell Carcinomas (DISCERN) Trial
DOI: 10.3390/cancers171017272024
Journal article
Assessment of perineural spread in advanced cutaneous squamous cell carcinomas treated with immunotherapy
DOI: 10.1186/s40644-024-00678-82024
Journal article
Evaluating the Utility of 18F-FDG PET/CT in Cancer of Unknown Primary
DOI: 10.2967/jnumed.123.267274
RECENT SCHOLARLY WORKS
2024
Conference Proceedings
Single Time Point Whole-Body Tumour Dosimetry as an Independent Prognostic Biomarker for Treatment Outcome in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Lutetium-177 [177Lu]Lu-PSMA-617
2024
Journal article
Optimising Patient Outcomes in Tongue Cancer: A Multidisciplinary Approach
DOI: 10.3390/cancers160712772023
Conference Proceedings
Inpatient admissions for hormone secretion management in patients with neuroendocrine neoplasms treated with [177Lu]Lu-DOTA-Octreotate therapy over a 3-year period at a single high volume treatment centre